Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 172
Filter
1.
Article in Chinese | WPRIM | ID: wpr-927349

ABSTRACT

OBJECTIVE@#To observe the effect of electroacupuncture on motor function and muscle state in patients with primary osteoporosis (POP).@*METHODS@#A total of 60 female patients with POP were randomized into an observation group (30 cases, 1 case dropped off) and a control group (30 cases, 1 case dropped off). On the basis of adjusting lifestyle, caltrate was given orally in the control group, 2 pills a day for 4 weeks. On the basis of the treatment in the control group, electroacupuncture was applied at Zusanli (ST 36), Yanglingquan (GB 34), Ganshu (BL 18), Pishu (BL 20), Shenshu (BL 23), etc. in the observation group, with disperse-dense wave of 2 Hz/10 Hz in frequency, once every other day, 3 times a week for 4 weeks. The time of timed up-and-go test (TUGT) and the value of 10 m maximal walking speed (10 m MWS) before and after treatment were compared in the two groups, and the Young's modulus values of bilateral multifidus muscles in prone position and sitting position before and after treatment were compared by real-time shear wave elastography (SWE) in the two groups.@*RESULTS@#After treatment, the TUGT time was decreased compared before treatment in the observation group (P<0.01), and that in the observation group was shorter than the control group (P<0.01). After treatment, the value of 10 m MWS test was increased compared before treatment in the observation group (P<0.05). After treatment, the Young's modulus values of bilateral multifidus muscles in prone position and sitting position were increased compared before treatment in the observation group (P<0.01); except for the left side in sitting position, the Young's modulus values of multifidus muscles in the observation group were higher than those in the control group (P<0.01, P<0.05).@*CONCLUSION@#On the basis of oral caltrate, electroacupuncture can improve the motor function and muscle state in patients with POP.


Subject(s)
Acupuncture Points , Electroacupuncture , Female , Humans , Life Style , Osteoporosis/therapy , Paraspinal Muscles
2.
Rev. medica electron ; 43(2): 3192-3201, mar.-abr. 2021.
Article in Spanish | LILACS, CUMED | ID: biblio-1251936

ABSTRACT

RESUMEN En los adultos mayores existen múltiples enfermedades que afectan su calidad de vida y el logro de una longevidad satisfactoria. Una de ellas es la osteoporosis, enfermedad de elevada incidencia a nivel mundial, lo cual también se refleja en Cuba. Siendo una afección que conlleva a un alto grado de discapacidad, constituye un problema en el campo de la salud y de magnitud epidémica, más aún cuando la supervivencia de la humanidad tiende al aumento. Con el objetivo de estructurar los referentes teóricos sobre la osteoporosis, que contribuyan a la capacitación de médicos y estudiantes de Medicina como promotores de salud en prevención primaria de esta enfermedad, se realizó el siguiente artículo científico. Los factores que predisponen la aparición de la enfermedad son diversos, algunos modificables. Se señaló la importancia de su prevención, diagnóstico y tratamiento, así como formas de actuar sobre la misma, para modificar estilos de vida en la comunidad (AU).


ABSTRACT There are many diseases affecting life quality and the achievement of a satisfactory longevity in elder people; osteoporosis, a disease of high incidence around the world that also strikes in Cuba, is found among them. It is an affection leading to a high disability level, being a problem in the health field with an epidemic magnitude, even more when the human kind survival tends to increase. The current scientific article was written with the objective of structuring the theoretical referents on osteoporosis contributing to train Medicine doctors and students as health promoters in the primary prevention of this disease. The factors predisposing the disease's appearance are different, some of them modifiable. It is also stated the importance of its prevention, diagnosis and treatment, and also forms and ways of working on it to modify life styles in the community (AU).


Subject(s)
Humans , Male , Female , Aged , Osteoporosis/epidemiology , Aged/physiology , Osteoporosis/complications , Osteoporosis/diagnosis , Osteoporosis/prevention & control , Osteoporosis/therapy , Quality of Life , Disabled Persons/rehabilitation , Life Style
3.
Rev. chil. endocrinol. diabetes ; 14(2): 74-76, 2021.
Article in Spanish | LILACS | ID: biblio-1283555

ABSTRACT

La enfermedad de Gaucher (EG) es un trastorno genético lisosomal autosómico recesivo infrecuente, que conduce a la acumulación de lípidos y disfunción en múltiples órganos. La afectación del esqueleto es uno de los hallazgos más frecuentes de la EG y una de las principales causas de dolor y reducción de calidad de vida. El compromiso esquelético incluye anomalías en el remodelado óseo con pérdida mineral ósea, adelgazamiento cortical, lesiones líticas, fracturas por fragilidad y deformidades articulares. A continuación presentamos el caso de una paciente 61 años con osteoporosis grave secundaria a EG diagnosticada en la vida adulta, con antecedente de dos hermanas con EG. La paciente refería dolores óseos y lumbago crónico desde los 53 años. El 2012 fue evaluada en policlínico de hematología por trombocitopenia y debido a sus antecedentes familiares se le solicitaron exámenes que fueron compatibles con EG. El año 2016 la densitometría ósea (DXA) de columna lumbar y cuello femoral izquierdo, que mostró una osteoporosis. Se inició tratamiento con Alendronato, Calcio y Vitamina D, pero la paciente tuvo escasa adherencia. El 2018 se inició tratamiento de su EG con Taliglucerasa α. Al año siguiente se le realizó nueva DXA que evidenció persistencia de la osteoporosis y por mantención del lumbago se le solicitó una TAC de columna lumbar que mostró fracturas por aplastamiento de cuerpos vertebrales dorsales bajos. Se derivó a endocrinología para manejo de su osteoporosis grave. A su ingreso a endocrinología la paciente persitía con dolor lumbar alto y destacaba una marcada cifosis. Se decidió retomar tratamiento con Alendronato, calcio y vitamina D, además, se le solicitó una nueva evaluación densitométrica junto a una radiografía de columna total y evaluación dental. Durante el seguimiento la paciente mantuvo niveles de vitamina D adecuados con funciones renal, hepática y tiroidea normales.


Gaucher disease (GD) is a rare autosomal recessive lysosomal genetic disorder, leading to the accumulation and dysfunction of lipids in multiple organs. Skeletal involvement is one of the most prevalent aspects of GD and one of the main causes of pain and reduced quality of life. Abnormalities of bones, which cause changes in the development and loss of bone mineral, cortical thinning, lytic lesions,fragility fractures and deformities. We present a case of a patient diagnosed with severe osteoporosis, secondary to GD diagnosed in adult life. The patient presents a disease pattern composed of bone pain and chronic low back pain since the age of 53. In 2012, she was evaluated at the hematology for thrombocytopenia and due to her family history, tests were performed to diagnose GD, which were compatible with it. In 2016 Bone Densitometry (DXA) of the lumbar spine and left femoral neck was requested, being consistent with osteoporosis. Treatment with Alendronate, Calcium and Vitamin D was started, however, there is little adherence. In 2018, treatment for Gaucher's disease was started with Taliglucerase α. The following year, DXA was performed with few changes and a CT scan of the lumbar spine was performed diagnosing crush fractures of the low dorsal vertebral bodies. She was referred to endocrinology. Upon admission to Endocrinology, it was decided to resume initial osteoporosis treatment and to perform skeletal evaluation with DXA of the lumbar spine and hips, total spine X-ray and dental evaluation. During follow-up, it maintains vitamin D at adequate levels and normal kidney, liver and thyroid functions.


Subject(s)
Humans , Female , Middle Aged , Osteoporosis/etiology , Gaucher Disease/complications , Osteoporosis/therapy , Low Back Pain/etiology
4.
Actual. osteol ; 16(2): [132]-[140], mayo.-ago. 2020. ilus
Article in Spanish | LILACS | ID: biblio-1129806

ABSTRACT

La oxitocina (OXT) como la arginina-vasopresina (AVP) son dos hormonas primitivas secretadas por la hipófisis posterior. Sus receptores están mucho más ampliamente distribuidos en el organismo de lo que se pensaba originalmente, incluido el hueso. En los estudios preclínicos, la OXT ha mostrado ser anabólica para el hueso, promoviendo la osteogénesis sobre la adipogénesis y favoreciendo la actividad osteoblástica sobre la osteoclástica. Tanto los osteoblastos como los osteoclastos tienen receptores para la OXT, y los efectos de los estrógenos sobre la masa ósea en ratones está mediada por lo menos en parte por la OXT. El mecanismo preciso por el cual la activación de los receptores de oxitocina (OXTR) se traduce en un incremento de la formación ósea permanece poco claro. La AVP también podría afectar el esqueleto en forma directa. Dos de los receptores de la AVP, V1a y V2 están expresados en osteoblastos y osteoclastos. La inyección de AVP en ratones de tipo salvaje aumenta la formación osteoclastos que producen resorción y reduce los osteoblastos formadores de hueso. En forma opuesta, la exposición de precursores osteoblásticos a antagonistas de los receptores V1a o V2, incrementan la osteoblastogénesis, como también lo hace la deleción genética del receptor V1a. (AU)


Both oxytocin (OXT) and argininevasopressin (AVP) are primitive hormones secreted by the posterior pituitary gland. OXT receptors are much more widely distributed in the body than originally thought, including in bone. In preclinical studies, OXT has been shown to be anabolic for bone, promoting osteogenesis over adipogenesis and favoring osteoblastic over osteoclastic activity. Both osteoblasts and osteoclasts have receptors for OXT, and the effects of estrogen on bone mass in mice is mediated at least in part by OXT. The precise mechanism by which the activation of oxytocin receptors (OXTRs) results in an increase in bone formation remains unclear. AVP could also have direct actions on the skeleton. The two AVP receptors, V1a and V2, are expressed in osteoblasts and osteoclasts. Injection of AVP in wild-type mice increases the formation of osteoclasts increasing bone resorption, and reduces bone-forming osteoblasts. On the contrary, the exposure of osteoblastic precursors to V1a and V2 antagonists increase osteoblastogenesis, the same as the genetic deletion of the V1a receptor. (AU)


Subject(s)
Humans , Animals , Mice , Pituitary Hormones, Posterior/biosynthesis , Arginine Vasopressin/adverse effects , Oxytocin/therapeutic use , Osteoblasts/physiology , Osteoclasts/physiology , Osteogenesis , Osteoporosis/therapy , Pituitary Hormones, Posterior/physiology , Arginine Vasopressin/antagonists & inhibitors , Arginine Vasopressin/biosynthesis , Arginine Vasopressin/physiology , Arginine Vasopressin/therapeutic use , Oxytocin/biosynthesis , Oxytocin/adverse effects , Oxytocin/physiology , Signal Transduction , Bone Density , Bone Density/drug effects , Receptors, Oxytocin/biosynthesis , Receptors, Oxytocin/physiology , Estradiol/therapeutic use , Estrogens/physiology
5.
Rev. cuba. ortop. traumatol ; 34(1): e265, ene.-jun. 2020. ilus
Article in Spanish | LILACS, CUMED | ID: biblio-1139104

ABSTRACT

RESUMEN Introducción: La osteoporosis es la enfermedad ósea más común de los adultos mayores y constituye un importante problema de salud pública en todo el mundo. Objetivo: Actualizar algunos conceptos sobre osteoporosis y su tratamiento. Métodos: Se realizó una revisión de publicaciones entre 2010-2020 en inglés, con los términos: "osteoporosis", "tratamiento de la osteoporosis", "fracturas por osteoporosis". Resultados: La osteoporosis tiene gran impacto no solamente desde el ámbito clínico, sino también económico y social. Su tratamiento incluye medidas generales y el empleo de diversos grupos de fármacos. La posibilidad de fracturas por fragilidad en muñeca, columna y cadera es considerable lo que determina morbilidad y mortalidad elevadas(AU)


ABSTRACT Introduction: Osteoporosis is the most common bone disease in aged adults and it constitutes a major public health problem throughout the world. Objective: To update concepts on osteoporosis and treatment. Methods: A review of publications from 2010 to 2020 in English was carried out, using the terms "osteoporosis", "treatment of osteoporosis", "osteoporosis fractures". Results: Osteoporosis has great impact not only clinically, but economically and socially as well. Its treatment includes general measures and the use of various groups of drugs. The possibility of fragility fractures in the wrist, spine and hip is significant, which determines high morbidity and mortality(AU)


Subject(s)
Humans , Osteoporosis/therapy , Health Knowledge, Attitudes, Practice , Osteoporotic Fractures/prevention & control
6.
Arch. argent. pediatr ; 118(3): e300-e304, jun. 2020. ilus, tab
Article in Spanish | LILACS, BINACIS | ID: biblio-1116991

ABSTRACT

La osteoporosis es un trastorno para tener en cuenta en niños con patologías crónicas graves o con algunas enfermedades genéticas que predisponen al incremento de la fragilidad ósea. La osteoporosis primaria es una entidad con etiologías emergentes y puede ocurrir en forma sindrómica. La asociación con pliegues retinianos congénitos debe orientar al diagnóstico de osteoporosis-pseudoglioma (OMIM 259770), síndrome poco frecuente (prevalencia de 1/2000000), que se origina por la pérdida de función de la proteína LRP5 (low-density lipoprotein receptor-related protein 5) y compromete la vía de señalización de Wnt/ß-catenina. Se presenta el caso de un niño con pliegues retinianos congénitos, ceguera progresiva y múltiples fracturas cuyo estudio clínico, bioquímico y genético confirmó el diagnóstico de osteoporosis primaria debido a una nueva variante inactivante en el gen LRP5 en homocigosis


Osteoporosis should be considered in children with severe chronic diseases or in association with some genetic diseases that bear an increased risk of bone fragility. Primary osteoporosis is an entity in which emerging aetiologies are being recognized. Its association with congenital retinal folds should guide the diagnosis to the Osteoporosis-Pseudoglioma syndrome (OMIM 259770), a rare disease (prevalence of 1/2000000), caused by the loss of function of the protein LRP5 (low-density lipoprotein receptor-related protein 5) resulting in the alteration of the Wnt/ß-catenin signalling pathway. We report the case of a child with congenital retinal folds, progressive loss of vision and multiple fractures whose clinical, biochemical and genetic studies confirmed the diagnosis of primary osteoporosis due to a novel homozygous inactivating variant in LRP5


Subject(s)
Humans , Male , Child , Osteoporosis/diagnosis , Osteoporosis/therapy , Blindness , Fractures, Multiple
7.
Actual. osteol ; 16(1): 47-66, Ene - abr. 2020. ilus
Article in Spanish | LILACS | ID: biblio-1140035

ABSTRACT

La "razón de ser" de nuestros huesos y esqueletos constituye un dilema centralizado en los conceptos biológicos de "estructura" y "organización", cuya solución necesitamos comprender para interpretar, diagnosticar, tratar y monitorear correctamente las osteopatías fragilizantes. Últimamente se ha reunido conocimiento suficiente para proponer aproximaciones razonables a ese objetivo. La que exponemos aquí requiere la aplicación de no menos de 6 criterios congruentes: 1) Un criterio cosmológico, que propone un origen común para todas las cosas; 2) Un criterio biológico, que explica el origen común de todos los huesos; 3) Un enfoque epistemológico, que desafía nuestra capacidad de comprensión del concepto concreto de estructura y del concepto abstracto de organización, focalizada en la noción rectora de direccionalidad espacial; 4) Una visión ecológica, que destaca la importancia del entorno mecánico de cada organismo para la adecuación de la calidad mecánica de sus huesos a las "funciones de sostén" que les adjudicamos; 5) Una correlación entre todo ese conocimiento y el necesario para optimizar nuestra aptitud para resolver los problemas clínicos implicados y 6) Una jerarquización del papel celular en el manejo de las interacciones genético-ambientales necesario para asimilar todo el problema a una simple cuestión de organización direccional de la estructura de cada hueso. Solo aplicando estos 6 criterios estaríamos en condiciones de responder a la incógnita planteada por el título. La conclusión de esta interpretación de la conducta y función de los huesos debería afectar el fundamento de la mayoría de las indicaciones farmacológicas destinadas al tratamiento de la fragilidad ósea. (AU)


The nature of the general behavior of our bones as weight-bearing structures is a matter of two biological concepts, namely, structure and organization, which are relevant to properly interpret, diagnose, treat, and monitor all boneweakening diseases. Different approaches can be proposed to trace the corresponding relationships. The one we present here involves six congruent criteria, namely, 1) a cosmological proposal of a common origin for everything; 2) a biological acknowledgement of a common origin for all bones; 3) the epistemological questioning of our understanding of the concrete concept of structure and the abstract notion of organization, focused on the lead idea of directionality; 4) the ecological insight that emphasizes the relevance of the mechanical environment of every organism to the naturally-selected adjustment of the mechanical properties of their mobile bones to act as struts or levers; 5) The clinical aspects of all the alluded associations; 6) The central role of bone cells to control the genetics/ environment interactions of any individual as needed to optimize the directionality of the structure of each of his/her bones to keep their mechanical ability within physiological limits. From our point of view, we could only solve the riddle posed by the title by addressing all of these six criteria. The striking conclusion of our analysis suggests that the structure (not the mass) of every bone would be controlled not only to take care of its mechanical ability, but also to cope with other properties which show a higher priority concerning natural selection. The matter would be that this interpretation of bone behavior and 'function' should affect the rationales for most pharmacological indications currently made to take care of bone fragility. (AU)


Subject(s)
Humans , Bone and Bones/physiology , Bone Diseases, Metabolic/diagnosis , Osteogenesis Imperfecta/diagnosis , Osteogenesis Imperfecta/therapy , Osteoporosis/diagnosis , Osteoporosis/therapy , Bone and Bones/anatomy & histology , Bone and Bones/cytology , Bone and Bones/ultrastructure , Bone Diseases, Metabolic/therapy , Epigenesis, Genetic
8.
Actual. osteol ; 15(2): 94-102, mayo - ago. 2019. tab.
Article in Spanish | LILACS | ID: biblio-1048478

ABSTRACT

El propósito de la terapia en el desorden del metabolismo óseo mineral asociado a la enfermedad renal crónica (IRC) consiste en restaurar el balance mineral, y, en la osteoporosis, mantener o aumentar la masa ósea. Ambas terapias tratan de evitar la fractura ósea. La mayoría de los osteoactivos están contraindicados en la insuficiencia renal crónica avanzada (estadios 4 y 5), y las terapias son empíricas. Algunos autores opinan que sin anomalías bioquímicas del desorden del metabolismo óseo mineral asociado a la enfermedad renal crónica avanzada se podría intentar el tratamiento estándar para la osteoporosis. Antes de intentar la terapia osteoactiva se debe corregir el desorden mineral óseo que pudiera presentarse asociado a la IRC, y en la indicación del tipo de osteoactivo se sugiere seleccionar al paciente según su estado óseo. Se aconseja que la administración de los antirresortivos se realice a dosis menores con respecto a los que tienen mejor función renal junto con aportes adecuados de calcio y vitamina D, antes y durante el tratamiento para prevenir el riesgo de severas hipocalcemias y un efecto óseo excesivo. Se presenta el caso clínico de una mujer de 65 años, con diagnóstico de osteoporosis de etiología multifactorial, fractura de pelvis, múltiples fracturas vertebrales e insuficiencia renal crónica avanzada, entre otras comorbilidades, y probable enfermedad ósea adinámica. Recibió inicialmente terapia con teriparatide y luego con denosumab, complicándose con hipocalcemia asintomática. (AU)


The purpose of therapy for the bone mineral metabolism disorder associated with chronic kidney disease is to restore the mineral balance; and to maintain or increase bone mass in osteoporosis. The goal of both types of therapy is to avoid bone fractures. Most antiosteoporotic drugs are contraindicated in advanced chronic renal failure (CRF) stages 4 and 5, and the therapies are empirical. Some authors believe that without biochemical abnormalities of the mineral bone metabolism disorder associated with advanced chronic kidney disease, standard treatment for osteoporosis could be attempted. Before attempting antiosteoporotic therapy, the bone mineral disorder that may be associated with CRF must be corrected, and in the indication of the type drug it is suggested that the patient be selected according to their bone status. It is advised that the administration of anti-resorptives be performed at lower doses in individuals with poor renal function compared to those with better renal function together with adequate calcium and vitamin D, before and during treatment to prevent the risk of severe hypocalcemia, and an excessive bone effect. We present the clinical case of a 65-year-old woman with a diagnosis of osteoporosis of multifactorial etiology, pelvic fracture, multiple vertebral fractures and advanced chronic renal failure, among other comorbidities and probable adynamic bone disease. The patient received initial therapy with teriparatide and followed by denosumab administration and exhibited asymptomatic hypocalcemia. (AU)


Subject(s)
Humans , Female , Aged , Chronic Kidney Disease-Mineral and Bone Disorder/drug therapy , Fractures, Bone/prevention & control , Osteoporosis/therapy , Chronic Kidney Disease-Mineral and Bone Disorder/complications , Chronic Kidney Disease-Mineral and Bone Disorder/metabolism , Chronic Kidney Disease-Mineral and Bone Disorder/therapy , Vitamin D/administration & dosage , Vitamin D/therapeutic use , Calcium/administration & dosage , Calcium/therapeutic use , Alendronate/therapeutic use , Teriparatide/administration & dosage , Teriparatide/adverse effects , Teriparatide/therapeutic use , Diphosphonates/administration & dosage , Diphosphonates/adverse effects , Diphosphonates/therapeutic use , Cinacalcet/therapeutic use , Risedronic Acid/therapeutic use , Denosumab/administration & dosage , Denosumab/adverse effects , Denosumab/therapeutic use , Hypocalcemia/prevention & control
11.
Anon.
Rev. cuba. endocrinol ; 30(1): 1-45, ene.-abr. 2019. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1098983

ABSTRACT

Cinco años después de la primera reunión de consenso para la propuesta de una Guía cubana para el diagnóstico y tratamiento de la osteoporosis se produce en La Habana (15 de mayo de 2017), esta segunda reunión con el propósito de actualizarla. De manera general se mantienen iguales objetivos que en la anterior. En esta versión se incorporan nuevos grupos de riesgo para osteoporosis, se exponen resultados nacionales relacionados con la frecuencia de esta enfermedad, así como el resultado del estudio multicentro (Instituto Nacional de Endocrinología, Hospital Ginecobstétrico "Ramón González Coro", Hospital Provincial Universitario "Arnaldo Milián Castro" y Hospital Provincial Universitario "Camilo Cienfuegos Gorriarán") con alendronato de sodio genérico, relacionado con la prevención de fractura, y un resumen actualizado de los fármacos aprobados para el tratamiento de la osteoporosis. Se reafirman los criterios para diagnóstico y opciones terapéuticas, así como para evaluar la utilidad de la guía(AU)


Subject(s)
Humans , Osteoporosis/diagnosis , Osteoporosis/therapy , Practice Guideline , Densitometry/methods
12.
Rev. méd. Chile ; 147(2): 199-205, Feb. 2019. tab, graf
Article in Spanish | LILACS | ID: biblio-1004333

ABSTRACT

Background: As the population ages, patients exposed to osteoporotic fractures increase, especially hip fracture, which is the most severe and costly. Aim: To characterize surgical practices in the management of hip fractures in older patients through a nationwide survey of specialized hip surgeons dedicated to the care of these patients. Material and Methods: A survey composed of 32 questions was formulated, including demographic factors, preoperative evaluation, definitive treatment, and postoperative management. It was sent to 140 specialists. 84 of them replied (61%), and 71 answers were included. Results: Eighty six percent of respondents agreed that orthogeriatric management is fundamental in the outcome of these patients, but only 73% had the collaboration of an internist or a geriatrician. Although 97% considered 72 hours or less the ideal time to perform surgery, only 52% of the respondents declared performing surgery within that timeframe, with differences between private and public system. Regarding surgical treatment, 94-98% of femoral neck fractures are treated with an arthroplasty and 98-99% of per-subtrochanteric fractures are treated with internal fixation and osteosynthesis. Osteoporosis treatment is only carried out by 51% of the respondents and with significant variation. Conclusions: This survey shows that there is agreement in surgical practice between specialists treating these patients, but clear differences in preoperative optimization, treatment timeframe, and post fracture medical treatment.


Subject(s)
Humans , Middle Aged , Aged , Practice Patterns, Physicians'/statistics & numerical data , Surveys and Questionnaires , Orthopedic Surgeons/statistics & numerical data , Hip Fractures/surgery , Osteoporosis/therapy , Postoperative Care/statistics & numerical data , Chile , Electronic Mail , Femoral Neck Fractures/surgery , Time-to-Treatment , Fracture Fixation, Internal
13.
Braz. oral res. (Online) ; 33: e079, 2019. graf
Article in English | LILACS | ID: biblio-1019604

ABSTRACT

Abstract Cell therapy associated with guided bone regeneration (GBR) can be used to treat bone defects under challenging conditions such as osteoporosis. This study aimed to evaluate the effect of mesenchymal stem cells (MSCs) in combination with a poly(vinylidene-trifluoroethylene)/barium titanate (PVDF-TrFE/BT) membrane on bone repair in osteoporotic rats. Osteoporosis was induced in female rats by bilateral removal of the ovaries (OVX) or sham surgery (SHAM), and the osteoporotic condition was characterized after 5 months by microtomographic and morphometric analyses. Calvarial defects were created in osteoporotic rats that immediately received the PVDF-TrFE/BT membrane. After 2 weeks, bone marrow-derived MSCs from healthy rats, characterized by the expression of surface markers using flow cytometry, or phosphate-buffered saline (PBS) (Control) were injected into the defects and bone formation was evaluated 4 weeks post-injection by microtomographic, morphometric, and histological analyses. A reduction in the amount of bone tissue in the femurs of OVX compared with SHAM rats confirmed the osteoporotic condition of the experimental model. More bone formation was observed when the defects were injected with MSCs compared to that with PBS. The modification that we are proposing in this study for the classical GBR approach where cells are locally injected after a membrane implantation may be a promising therapeutic strategy to increase bone formation under osteoporotic condition.


Subject(s)
Animals , Female , Polyvinyls/pharmacology , Titanium/pharmacology , Barium Compounds/pharmacology , Guided Tissue Regeneration/methods , Mesenchymal Stem Cells/physiology , Osteogenesis/drug effects , Osteoporosis/physiopathology , Osteoporosis/therapy , Polyvinyls/chemistry , Time Factors , Titanium/chemistry , Bone Regeneration/drug effects , Bone Regeneration/physiology , Ovariectomy , Random Allocation , Bone Density , Reproducibility of Results , Treatment Outcome , Rats, Wistar , Barium Compounds/chemistry , Imaging, Three-Dimensional , Mesenchymal Stem Cells/chemistry , Flow Cytometry
14.
Rev. med. Rosario ; 84(3): 138-138, sept.-dic. 2018.
Article in Spanish | LILACS | ID: biblio-1051387

ABSTRACT

La osteoporosis afecta al 6-7% de la poblaciónmasculina. Es alta la proporción de pacientes confractura osteoporótica sin diagnóstico previo de estaenfermedad. La mortalidad luego de una fracturaes mayor en hombres que en población femenina;a pesar de esto, la mayoría de los pacientes no reciben tratamiento. Los fármacos aprobados, en nuestro medio, para tratar la osteoporosis masculina son:bifosfonatos, teriparatida y ranelato de estroncio. Elobjetivo de este estudio fue evaluar el efecto del ranelato de estroncio sobre la densidad mineral ósea enhombres después de 1 año de tratamiento. Se incluyeron los registros de 20 hombres de 67.8±3.0 años,tratados con ranelato de estroncio (2 g/día) durante 1año. Todos los pacientes presentaban un T-score inferior a -2.5 en cadera o columna vertebral o un T-scoreinferior a -2.0 y factores de riesgo de fractura. Nohubo modificación de parámetros de laboratorio luego del tratamiento (calcemia, calciuria, fósforo sérico,parathormona, 25(OH)vitamina D, fosfatasa alcalinay desoxipiridinolina). Luego de 1 año de tratamiento con ranelato de estroncio se observó incrementode la densidad mineral ósea en columna lumbar:0.953±0.029 versus 0.997±0.030 g/cm2 (p=0.0068),cuello femoral: 0.734±0.013 versus 0.764±0.016 g/cm2 (p=0.0084) y cadera total: 0.821±0.02 versus0.834±0.02 g/cm2 (p=0.0419). Conclusión: luego de1 año de tratamiento el ranelato de estroncio produjoun incremento significativo de la densidad mineralósea en columna lumbar y fémur proximal en hombres con osteoporosis (AU)


Osteoporosis affects 6-7% of the male population. The proportion of patients with fragility fractures but without diagnosis of the disease is high. Mortality after hip fracture is higherin men than in women; in spite of this, mostpatients are left without treatment for osteoporosis. Drugs approved, for the treatment ofosteoporosis in our country are bisphosphonates, teriparatide, and strontium ranelate (SrR).The objective of this study was to evaluate theeffect of SrR on axial BMD in men after one yearof treatment. We obtained pertinent data frommedical registries of 20 men aged 67,8±3,0 years,treated with oral SrR (2 g/day) for 12 months. All patients had a T-score below -2,5 at the hipor the lumbar spine, or a T-score below -2,0and one or more risk factors for fracture. Thelevels of serum calcium, phosphate, alkalinephosphatase, 25-hydroxyvitamin D, or PTH,or urinary calcium and desoxipyridinoline remained unchanged following SrR administration. After treatment with SrR there weresignificant increases in BMD at the lumbarspine: 0,953±0,029 versus 0,997±0,030 g/cm2(p=0,0068), femoral neck: 0,734±0,013 versus 0,764±0,016 g/cm2 (p=0.0084), and total hip: 0,821±0,02 versus 0,834±0,02 g/cm2(p=0,0419). Conclusion: in osteoporotic men,treatment with SrR significantly increases BMDin the lumbar spine and the proximal femur (AU)


Subject(s)
Humans , Male , Adult , Aged , Osteoporosis/drug therapy , Osteoporosis/therapy , Spine/drug effects , Spine/pathology , Bone Density , Men's Health , Femur/drug effects , Femur/pathology
15.
Rev. chil. reumatol ; 34(3): 122-127, 2018.
Article in Spanish | LILACS | ID: biblio-1254233

ABSTRACT

El manejo del dolor articular ofrece para la población afectada novedosos suplementos nutricionales que incluyen el colágeno, y cuya extracción es desde variadas fuentes de origen animal, no así de vegetales. Esta revisión tiene como objetivo aclarar qué es el colágeno, su constitución estructural molecular, el rol que cumple en nues-tro organismo y revisar las indicaciones propuestas por la literatura, tanto para la profilaxis como el tratamiento de cuadros reumatológicos de alta prevalencia o impacto funcional, como son Artrosis, Artritis Reumatoidea y Osteoporosis.


Novel nutritional supplements for the management of joint pain have been made available to the population, including collagen, which can not be extracted from plant products, but from a variety of animal sources. This review aims to clarify what it is collagen, the molecular structures that constitute it, the determined role they play in our body and review the indications that the literature proposes both in prophylaxis and treatment, for high prevalence rheumatologic or functional impact, such as osteoarthritis, rheumatoid arthritis and osteoporosis.


Subject(s)
Humans , Rheumatic Diseases/therapy , Collagen/therapeutic use , Osteoarthritis/therapy , Osteoporosis/therapy , Arthritis, Rheumatoid/therapy , Extracellular Matrix
16.
Rev. chil. obstet. ginecol. (En línea) ; 82(6): 639-648, Dec. 2017. tab, graf
Article in Spanish | LILACS | ID: biblio-899956

ABSTRACT

La osteoporosis es un desorden esquelético que afecta aproximadamente al 21% de las mujeres entre 50 y 84 años. Su importancia radica en que se asocia a un aumento en el riesgo de fractura, y por lo tanto, a un incremento en la morbimortalidad. El diagnóstico puede ser realizado mediante historia clínica o densitometría mineral ósea. Teniendo en cuenta que el sobrediagnóstico y sobretratamiento de osteoporosis en la práctica ginecológica es frecuente, es esencial conocer tanto las indicaciones para realizar densitometría como los criterios diagnósticos de la patología. El primer pilar para la prevención y tratamiento de osteoporosis es el ejercicio y el aporte adecuado de calcio y vitamina D. Los bifosfonatos son la terapia médica de primera línea, sin embargo, existen otras alternativas que han ha demostrado disminuir el riesgo de fractura osteoporótica como la terapia hormonal de la menopausia y el denosumab.


Osteoporosis is a skeletal disorder that affects approximately 21% of women between 50 and 84 years. It's an important public health issue because low bone mass leads to an increased risk of fracture, having negative consequences in morbidity and mortality in this population. Diagnosis is based in clinical history and bone densitometry. Over diagnosis and over treatment of osteoporosis is common in gynecologic practice. The knowledge of diagnostic criteria and indications to perform bone densitometry is relevant. Treatment of osteoporosis consists in lifestyle measures like exercise and adequate consumption of calcium and vitamin D. Bisphosphonates are first-line medical therapy, but alternative treatments including hormone replacement therapy and denosumab have also shown to decrease risk of fracture.


Subject(s)
Humans , Female , Osteoporosis/diagnosis , Osteoporosis/therapy , Osteoporosis/physiopathology , Vitamin D/therapeutic use , Exercise , Calcium/therapeutic use , Bone Remodeling , Hormone Replacement Therapy , Densitometry , Diphosphonates/therapeutic use , Fractures, Bone/prevention & control
17.
Lima; s.n; 2017. 66 p. tab, graf, ilus.
Thesis in Spanish | LILACS, MTYCI | ID: biblio-877264

ABSTRACT

Introducción: La osteoporosis es un trastorno del metabolismo óseo que predispone a fracturas con una alta carga de morbilidad asociada. Otros autores han comprobado experimentalmente la propiedad antiresortiva del extracto etanólico de los ecotipos rojo y negro de Lepidium meyenii, "maca", el cual incluye diversos metabolitos. Por ello, hace falta estudios que determinen el efecto de la fracción alcaloidal en la osteoporosis. Objetivo: Demostrar el efecto protector del extracto alcaloidal de Lepidium meyenii ecotipo amarillo sobre la osteoporosis inducida en ratas ovariectomizadas. Diseño: analítico, experimental incompleto. Participantes: 50 ratas. Lugar: Instituto de Patología de UNMSM, 2015. Método: división aleatoria en 5 grupos de 10 cada uno: operación simulada (sham) y ovarectomizadas con tratamiento: estradiol (40µg/Kg), extracto alcaloidal (EA) a dosis de 75mg/k y 100mg/k (maca I y II respectivamente), y sin tratamiento protector. Dosis diarias vía orogástrica por 8 semanas. Posteriormente se determinó densidad mineral ósea (DMO), marcadores óseos: fosfatasa alcalina (FA), osteocalcina, telopéptido amino terminal del colágeno (NTX), estradiol, calcio y fósforo en suero; y histomorfometría. Resultados: No se evidenciaron cambios significativos en la densitometría vertebral, a nivel del fémur se evidenció disminución en el grupo maca II. La FA (141,90 ± 33,58UI/L) y la osteocalcina (38,578 ± 10,403ng/ml) mostraron niveles superiores no significativos, el nivel de estradiol con el grupo maca II fue superior no significativo. Los niveles de calcio y fósforo no mostraron variación. En la histomorfometría el grupo maca II (58,030 ± 4683) mostró mayor grosor trabecular significativamente. Conclusiones: se evidenció efecto protector antiresortivo parcial en los cambios inducidos por la ovariectomización, sin embargo, no se indujo osteoporosis al no encontrarse variación en los niveles de DMO.


Subject(s)
Animals , Rats , Lepidium , Osteoporosis/therapy , Protective Agents , Alkaloids , Plant Extracts
18.
Rev. bras. reumatol ; 57(supl.2): s497-s514, 2017. tab
Article in English | LILACS | ID: biblio-899482

ABSTRACT

Abstract Osteoporosis, a metabolic disease characterized by low bone mass, deterioration of the bone tissue microarchitecture and increased susceptibility to fractures, is commonly regarded as a women's health problem. This point of view is based on the fact that compared with men, women have lower bone mineral density and longer lifespans and lose bone mass faster, especially after menopause, due to a marked decrease in serum estrogen levels. However, in the last 20 years, osteoporosis in men has become recognized as a public health problem due to the occurrence of an increasingly higher number of fragility fractures. Approximately 30% of all hip fractures occur in men. Recent studies show that the probability of fracture due to hip, vertebral or wrist fragility in Caucasian men older than fifty years, for the rest of their lives, is approximately 13% versus a 40% probability of fragility fractures in women. Men show bone mass loss and fractures later than women. Although older men have a higher risk of fracture, approximately half of all hip fractures occur before the age of 80. Life expectancy is increasing for both sexes in Brazil and worldwide, albeit at a higher rate for men than for women. This Guideline was based on a systematic review of the literature on the prevalence, etiology, diagnosis and treatment of osteoporosis in men.


Resumo Osteoporose, uma doença metabólica caracterizada por baixa massa óssea, deterioração da microarquitetura do tecido ósseo e aumento da suscetibilidade a fraturas, é comumente vista como um problema de saúde feminino. Essa visão tem fundamentos: em comparação com os homens as mulheres têm densidade mineral óssea menor, têm vida mais longa e perdem massa óssea mais rapidamente, principalmente após a menopausa, devido à diminuição acentuada dos níveis séricos de estrógeno. Entretanto, nos últimos 20 anos a osteoporose no homem tem sido reconhecida como um problema de saúde pública devido à ocorrência cada vez maior de fraturas por fragilidade. Cerca de 30% de todas as fraturas de quadril ocorrem em homens. Estudos recentes mostram que a probabilidade de fratura por fragilidade do quadril, vértebra ou punho em homens brancos após os 50 anos, pelo resto de suas vidas, situa-se em torno de 13%, 40% nas mulheres. Os homens apresentam perda de massa óssea e fraturas mais tardiamente do que as mulheres. Embora os homens mais idosos tenham maior risco de fratura, cerca de metade das fraturas de quadril ocorre antes dos 80 anos. A expectativa de vida tem aumentado para ambos os sexos no Brasil e em todo o mundo, porém em uma velocidade maior para homens do que para mulheres. Esta Diretriz foi baseada em uma revisão sistemática da literatura com relação a prevalência, etiologia, diagnóstico e tratamento da osteoporose em homens.


Subject(s)
Humans , Male , Adult , Aged , Aged, 80 and over , Osteoporosis/diagnosis , Osteoporosis/therapy , Rheumatology , Societies, Medical , Brazil , Absorptiometry, Photon , Middle Aged
19.
Rev. bras. ortop ; 52(5): 538-543, 2017. tab, graf
Article in English | LILACS | ID: biblio-899183

ABSTRACT

ABSTRACT Objective: To measure the prevalence of primary drug prevention of fractures due to osteoporosis in patients admitted to a tertiary teaching hospital, in a medium-sized city, admitted with osteoporotic fractures. Moreover, to identify the incidence of prescribing secondary prophylaxis after the first fracture event. At the same time, the prevalence of risk factors for such fractures as described in the literature was measured. Methods: This longitudinal prospective study was based on a cohort of patients admitted in a tertiary teaching hospital from October 2015 to January 2016. Patients with low energy or fragility fractures were included in the study regardless of gender or race, over the age of 50 years. All patients who did not have these characteristics were excluded. The follow-up lasted four months. Serial questionnaires were applied at admission and in the follow-up , consultations at four to eight weeks and at 16 weeks. Results: Only one patient reported receiving treatment with specific drugs for the disease before hospital admission, resulting in a prevalence of primary chemoprophylaxis of only 2.27%. No patient was prescribed medication for the treatment of osteoporosis after the fracture. The prevalence of risk factors was similar to those found in the literature review. Conclusion: In the present study, the frequency of primary and secondary osteoporosis chemoprophylaxis in patients who were admitted with fragility fractures was low, as well as the early indication of drug treatment after the first fracture. The prevalence of fragility fracture risk factors is similar to those reported in the literature.


RESUMO Objetivo: Medir a prevalência da profilaxia medicamentosa primária de fraturas por osteoporose em pacientes internados em um hospital terciário de ensino, em uma cidade de médio porte, admitidos com fraturas osteoporóticas. Além disso, identificar a incidência de prescrição de profilaxia medicamentosa secundária após o evento da primeira fratura. Paralelamente, medimos a prevalência de fatores de risco para fratura por osteoporose descritos na literatura. Método: Estudo longitudinal de uma coorte prospectiva de pacientes admitidos em hospital terciário de ensino de outubro de 2015 a janeiro 2016. Foram incluídos pacientes com fraturas de baixa energia ou por fragilidade, independentemente do gênero ou etnia, acima de 50 anos. Todos os pacientes que não apresentavam essas características foram excluídos. O seguimento foi de quatro meses. Foram aplicados questionários seriados na admissão, no retorno com quatro a oito semanas e com 16 semanas. Resultado: Somente um paciente referiu ter recebido tratamento com drogas específicas para a doença antes da internação hospitalar, o que revela uma prevalência de quimioprofilaxia primária de apenas 2,27%. Nenhum paciente recebeu prescrição para tratamento da osteoporose após a fratura. A prevalência dos fatores de risco de fratura se assemelha àquela encontrada na literatura. Conclusão: A frequência de quimioprofilaxia primária e secundária da osteoporose em pacientes admitidos com fraturas por fragilidade é baixa em nosso meio, assim como a indicação precoce de tratamento medicamentoso após a primeira fratura. A prevalência dos fatores de risco de fratura por fragilidade é semelhante àquela citada na literatura.


Subject(s)
Humans , Male , Female , Bone and Bones/injuries , Fractures, Bone/epidemiology , Osteoporosis/epidemiology , Osteoporosis/therapy , Primary Prevention , Risk Factors , Secondary Prevention
20.
Gastroenterol. latinoam ; 28(1): 16-24, 2017. tab, ilus
Article in Spanish | LILACS | ID: biblio-907663

ABSTRACT

This review corresponds to a general analysis of osteoporosis, with emphasis in calcium metabolism, the role of Vitamin D, as well as osteoporosis physiopathology, diagnosis and treatment. The second part (Osteoporosis. Part II) will describe the importance of osteoporosis in several digestive diseases (liver and gastrointestinal tract).


En esta revisión abordamos el tema osteoporosis en forma general, desarrollando principalmente el metabolismo del calcio, el rol de la vitamina D; así como la fisiopatología, el diagnóstico y tratamiento de la osteoporosis. En la segunda parte (Osteoporosis. Parte II ) se describirá la importancia de la osteoporosis en diversas enfermedades digestivas (hepáticas y del tubo digestivo).


Subject(s)
Humans , Osteoporosis/diagnosis , Osteoporosis/therapy , Calcium , Osteoporosis/metabolism , Osteoporosis/physiopathology , Vitamin D
SELECTION OF CITATIONS
SEARCH DETAIL